Evidence map›Paper›PMID 38969367›Full record

ArticleBMJ open2024

Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration.

Kristy P Robledo, Shilo Lefresne, Yu Yang Soon, Arjun Sahgal, Mark B Pinkham, Alan Nichol, Ross Andrew Soo, Ambika Parmar, Fiona Hegi-Johnson, Mark Doherty and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases FromJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Kristy P RobledoNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South Wales, Australia kristy.robledo@sydney.edu.au.ORCID 0000-0003-0213-7652
Shilo LefresneBC Cancer Agency, Vancouver, British Columbia, Canada.
Yu Yang SoonNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South Wales, Australia.
Arjun SahgalPrincess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Mark B PinkhamRadiation Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Alan NicholBC Cancer Agency, Vancouver, British Columbia, Canada.
Ross Andrew SooNational University Cancer Institute, Singapore.
Ambika ParmarSunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Fiona Hegi-JohnsonPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-4543-8802
Mark DohertySt Vincent's University Hospital, Dublin, Dublin, Ireland.
Benjamin J SolomonPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
David B ShultzPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Ivan Wk ThamMount Elizabeth Hospital, Singapore.
Adrian G SacherPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Jeremy TeyNational University Cancer Institute, Singapore.ORCID 0000-0003-1363-446X
Cheng Nang LeongNational University Cancer Institute, Singapore.
Wee Yao KohNational University Cancer Institute, Singapore.
Yiqing HuangNational University Cancer Institute, Singapore.
Yvonne Li En AngNational University Cancer Institute, Singapore.
Jiali LowNational University Cancer Institute, Singapore.
Clement YongNational University Health System, Singapore.
Mei Chin LimNational University Health System, Singapore.
Ai Peng TanNational University Health System, Singapore.
Chee Khoon LeeNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, New South Wales, Australia.
Cheryl HoBC Cancer Agency, Vancouver, British Columbia, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with advanced non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (

methodsRandomised controlled trials will be eligible if they include participants with BM arising from ETHICS AND DISSEMINATION: Approved by each trial's ethics committee. Results will be relevant to clinicians, researchers, policymakers and patients, and will be disseminated via publications, presentations and media releases. PROSPERO REGISTRATION: CRD42022330532.

Indexed as

AcrylamidesAniline CompoundsBrain NeoplasmsCarcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsRadiosurgerySystematic Reviews as TopicAntineoplastic AgentsCombined Modality TherapyHumansIndolesMeta-Analysis as TopicMutationProspective StudiesPyrimidinesAcrylamidesAniline CompoundsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsIndolesosimertinibPyrimidinesClinical trialsMeta-AnalysisONCOLOGYPatientsRadiation oncologyRespiratory tract tumours

Identifiers

PMID38969367
PMCPMC11227758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.